Keith Kleeman, Optimvia CEO
In pursuit of better heparin manufacturing process, Ginkgo teams up with an Ohio-based biotech
The manufacturing process to make biosynthetic heparin, a drug used for preventing blood clots, is not a particularly clean one.
In a slaughterhouse, someone must …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
